All questionsPharmacology: Skyrizi (risankizumab-rzaa), all indications1 question · 1 sourcePharmacokineticsHow is Skyrizi metabolized?“The metabolic pathway of risankizumab-rzaa has not been characterized. As a humanized IgG1 monoclonal antibody, risankizumab-rzaa is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.” (opens the source at this quote in a new tab)CopyFlag